ADAGENE INC-ADR (ADAG) Stock Price, Quote, News and Overview
NASDAQ:ADAG - Nasdaq - US0053291078 - ADR - Currency: USD
ADAG Quote, Performance and Key Statistics
ADAGENE INC-ADR
NASDAQ:ADAG (2/7/2025, 10:31:44 AM)
1.77
-0.01 (-0.56%)
The current stock price of ADAG is 1.77 USD. In the past month the price decreased by -13.62%. In the past year, price decreased by -51.64%.
ADAG Latest News and Analysis
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular...
ADAG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.81B | ||
| AMGN | AMGEN INC | 14.82 | 157.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 928.14 | 121.90B | ||
| GILD | GILEAD SCIENCES INC | 22.03 | 121.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.8 | 79.22B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.22B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.11B | ||
| NTRA | NATERA INC | N/A | 22.77B | ||
| BIIB | BIOGEN INC | 8.68 | 20.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.23 | 15.48B |
Related stock screener links
About ADAG
Company Profile
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 174 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Company Info
ADAGENE INC-ADR
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
Suzhou JIANGSU 215123 CN
CEO: Peter (Peizhi) Luo
Employees: 174
Company Website: https://www.adagene.com/
Investor Relations: http://www.investor.adagene.com/
Phone: 8651287773632
ADAG FAQ
What is the stock price of ADAG?
The current stock price of ADAG is 1.77 USD.
What is the symbol for ADAGENE INC-ADR stock?
The exchange symbol of ADAGENE INC-ADR is ADAG and it is listed on the Nasdaq exchange.
On which exchange is ADAG stock listed?
ADAG stock is listed on the Nasdaq exchange.
Is ADAG a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ADAG, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ADAG.
Does ADAG stock pay dividends?
ADAG does not pay a dividend.
What is the Price/Earnings (PE) ratio of ADAG?
ADAG does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).
What is the Short Interest ratio of ADAG stock?
The outstanding short interest for ADAG is 0.23% of its float.
ADAG Technical Analysis
ADAG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADAG. ADAG has a bad profitability rating. Also its financial health evaluation is rather negative.
ADAG Financial Highlights
Over the last trailing twelve months ADAG reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS decreased by 14.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.6% | ||
| ROE | -56.28% | ||
| Debt/Equity | 0.15 |
ADAG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ADAG. The Buy consensus is the average rating of analysts ratings from 10 analysts.